Prinomide | CAS# 77639-66-8 (free base)| anti-inflammatory

MedKoo Cat#: 412742 | Name: Prinomide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Prinomide is a carbamoylpyrrolepropionitrile derivative patented by Ciba-Geigy A.-G. as a nonsteroidal anti-inflammatory drug that has disease-modifying activity in rheumatoid arthritis. In clinical trials, Prinomide demonstrate significant improvement in symptom score and laboratory variables.

Chemical Structure

Prinomide

CAS#77639-66-8 (free base)

Theoretical Analysis

MedKoo Cat#: 412742

Name: Prinomide

CAS#: 77639-66-8 (free base)

Chemical Formula: C15H13N3O2

Exact Mass: 267.1008

Molecular Weight: 267.29

Elemental Analysis: C, 67.40; H, 4.90; N, 15.72; O, 11.97

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

109636-76-2 (tromethamine) 77639-66-8 (free base) 77639-70-4 (trolamine)

Synonym

Prinomide; CGS10787B; CGS-10787B; CGS 10787B

IUPAC/Chemical Name

2-cyano-3-(1-methyl-1H-pyrrol-2-yl)-3-oxo-N-phenylpropanamide

InChi Key

KBQUAIAGRLAZGP-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H13N3O2/c1-18-9-5-8-13(18)14(19)12(10-16)15(20)17-11-6-3-2-4-7-11/h2-9,12H,1H3,(H,17,20)

SMILES Code

Cn1c(C(C(C(Nc2ccccc2)=O)C#N)=O)ccc1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 267.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Egger H, Itterly W, John V, Rodebaugh R, Shimanskas C, Stancato F, Kapoor A. Disposition and metabolism of prinomide in laboratory animals. Drug Metab Dispos. 1988 Jul-Aug;16(4):568-75. PMID: 2903025. 2: Kochak GM, Pai S, Iannucci R, Honc F, Kachmar D, Perrino P, Egger H. Prinomide tromethamine pharmacokinetics: mutually dependent saturable and competitive protein binding between prinomide and its own metabolite. Pharm Res. 1993 Jan;10(1):49-55. doi: 10.1023/a:1018916811904. PMID: 8430060. 3: Cohick CB, Furst DE, Quagliata S, Corcoran KA, Steere KJ, Yager JG, Lindsley HB. Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: correlation with erythrocyte sedimentation rate or C-reactive protein. J Lab Clin Med. 1994 May;123(5):721-7. PMID: 8195678. 4: Parrish DD, Schlosser MJ, Kapeghian JC, Traina VM. Activation of CGS 12094 (prinomide metabolite) to 1,4-benzoquinone by myeloperoxidase: implications for human idiosyncratic agranulocytosis. Fundam Appl Toxicol. 1997 Feb;35(2):197-204. doi: 10.1006/faat.1996.2270. PMID: 9038241. 5: Bird HA, Hill J, Dixon JS, Bojar R, Traficante A, Catalano MA, Adair SF, Liauw L, Sussman H, Rotman H, et al. A clinical and biochemical assessment of prinomide in patients with rheumatoid arthritis. J Rheumatol. 1989 Apr;16(4):448-54. PMID: 2664168. 6: Doughty JR, Goldberg RL, Schenkelaars EJ, Singh HN, Peppard J, Haston W, Blancuzzi VJ, Di Pasquale G. Relationship of blood markers to disease severity and drug efficacy in rat adjuvant arthritis. Agents Actions. 1991 Sep;34(1-2):129-31. doi: 10.1007/BF01993257. PMID: 1793016. 7: Schenkelaars EJ, Singh HN, Goldberg RL, Doughty JR, Peppard J, DiPasquale G, Quagliata F. Pharmacological modulation of rat monocytes: in vivo effects on Ia expression and interleukin-1 production. Agents Actions. 1991 Sep;34(1-2):66-9. doi: 10.1007/BF01993240. PMID: 1793054. 8: Akita S, Abe C, Hirose S. Effect of a new antirheumatic drug (CGS10787B) on antibody formation and delayed-type hypersensitivity in BALB/c mice. Int J Tissue React. 1988;10(4):199-205. PMID: 3266939. 9: Luders RC, Brunner LA. Automated sample preparation and chromatographic analysis: determination of CGS 10787B and related compounds. J Chromatogr Sci. 1987 May;25(5):192-7. doi: 10.1093/chromsci/25.5.192. PMID: 3597649.